Ariad Pharmaceuticals Inc.'s stock jumped after news of a victory valued at about $65.2 million in its patent lawsuit against Eli Lilly and Co. - though Lilly plans first to ask the judge to set aside the jury's verdict regarding Evista and Xigris and then to appeal, if necessary. (BioWorld Today)

On the heels of a potential $92 million deal with Ilypsa Inc. for Ilypsa's Phase I phosphate binder, Astellas Pharma Inc. has licensed early stage, oral anemia compounds from FibroGen Inc. in a pact worth $300 million up front plus milestones totaling as much as $465 million. (BioWorld Today)